-+ 0.00%
-+ 0.00%
-+ 0.00%

ALX Oncology Q1 FY26 net loss narrows 41.88% to $17.9 million

PUBT·05/08/2026 12:02:56
Listen to the news
ALX Oncology Q1 FY26 net loss narrows 41.88% to $17.9 million
  • ALX Oncology reported a GAAP net loss of USD 17.9 million, or USD 0.17 per share, for Q1 2026, narrowing from a GAAP net loss of USD 30.8 million, or USD 0.58 per share, a year earlier.
  • R&D expense fell 43.1% year over year to USD 13.6 million, while G&A expense dropped 32.9% to USD 5.4 million.
  • Cash, cash equivalents and investments totaled USD 169.1 million at March 31, 2026; ALX said it expects that balance to fund operations through the first half of 2028.
  • Phase 2 ASPEN-09-Breast trial remains on track for topline data for 80 patients in mid-2027; Phase 1 ALX2004 dose-escalation study is expected to deliver safety data in 2H 2026.
  • CEO Jason Lettmann said ESMO Breast Cancer 2026 data supported a CD47 biomarker-driven strategy for evorpacept in HER2-positive disease, citing durable responses in patients with high CD47 expression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080800PRIMZONEFULLFEED9716124) on May 08, 2026, and is solely responsible for the information contained therein.